HLB Pharmaceutical Acquires Samsung Pharmaceutical Hyangnam Plant... "Leap to Comprehensive Pharmaceutical and Bio Company"

[Asia Economy Reporter Yoo Hyun-seok] HL Biopharma announced on the 16th that it will acquire Samsung Pharm's Hyangnam plant. The acquisition of the pharmaceutical factory and facilities aims to expand pharmaceutical equipment to increase scale, diversify product lines, and prepare to function as a pipeline production base within the HL Group, the company stated.

The Hyangnam plant is three times the size of the Namyangju plant operated by HL Biopharma, and through this acquisition, HL Biopharma's production capacity (CAPA) is expected to be significantly expanded. Additionally, HL Biopharma's main products are tablets and capsules. With the acquisition of the Hyangnam plant, it will be possible to produce various products such as injectables, infusions, liquids, and oral suspensions.

Furthermore, the Hyangnam plant is expected to become a key production base for various new drug substances currently being developed within the HL Group.

According to the acquisition contract of the Hyangnam plant, Samsung Pharm will outsource the production of most products previously manufactured at the Hyangnam plant to HL Biopharma. As a result, HL Biopharma will secure production facilities along with stable sales and growth in operating profit.

Park Jae-hyung, CEO of HL Biopharma, emphasized, “The acquisition of the Hyangnam plant has laid the foundation for full-scale growth. Despite the acquisition, the company still maintains sufficient liquidity, and continuous operating profit is expected. By securing a new drug pipeline along with qualitative growth of the company, we will grow into a substantial comprehensive pharmaceutical and bio company.”

This content was produced with the assistance of AI translation services.